As sustainability pressures intensify across healthcare, one often-overlooked component is taking center stage: the propellant inside metered dose inhalers (MDIs). While invisible to patients, these propellants account for up to 95% of an inhaler’s formulation—and a significant share of its environmental footprint.
Andy Burns, Vice President of Business Development for MDI at Kindeva, a drug delivery CDMO that specializes in injectable, inhalation, and dermal products, explains what’s driving the shift,and what it means for pharma and packaging stakeholders.


















